SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

A Leerink downgrade and reduced outlook have put Bristol Myers pipeline and growth prospects in focus, with concerns around upcoming trial readouts and Cobenfy adoption. The cautious view contrasts with bullish posts highlighting positive multiple-myeloma data and Camzyos expanded pediatric indication.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Robinhoods use of Arbitrum for its chain and tokenized-asset activity is the main catalyst traders cite for ARBs rally, alongside expectations that growing network activity could generate more revenue. Optimists see that adoption as a long-term positive, while skeptics argue ARB holders may not benefit without stronger token value capture and remain wary of token unlocks.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Kodiaks positive Phase 3 DAYBREAK results have focused attention on competition in wet AMD and heightened concern that AXPAXLI may face a tougher bar, amid a sharp OCUL selloff. Bullish traders argue the trials are not directly comparable and point to AXPAXLIs SOL-1 results and planned NDA filing as reasons its durability profile remains differentiated.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

A sharp rally has traders focused on a breakout through a key psychological resistance level, with the anticipated AerodromeVelodrome merger and multi-chain expansion cited as potential catalysts. Sentiment is largely bullish, though some traders are watching for a pullback or questioning whether the gains will hold.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on new PrTK05 biomarker findings suggesting sustained immune activation after CAN-2409 treatment, alongside Candels statement that biodistribution and shedding data are compiled for its planned Q4 prostate-cancer BLA submission. Bulls view the findings and reiterated filing timeline as supportive, while skeptics question the limited biomarker data and BLA timing amid continued share-price weakness.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck and Modernas personalized mRNA melanoma vaccine met key Phase 3 endpoints when combined with Keytruda, lifting optimism about Mercks oncology pipeline and the potential to strengthen its franchise ahead of Keytrudas patent expiration. Traders are largely bullish on the validation, though some question how much the results justify in valuation given that full data, overall-survival results and regulatory progress remain outstanding.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and heavy volume have traders focused on a possible breakout, with bullish posts tying interest to Starknets privacy and post-quantum technology, Bitcoin DeFi plans, and speculation about a future shift from Ethereum L2 to L1. Sentiment is split between calls for further gains and warnings that the move could be a short-lived pump, with some traders watching for profit-taking and support levels.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is drawing attention as a low-cost, broad U.S. market fund for long-term, buy-and-hold investing, with traders praising diversification and steady accumulation. That optimism contrasts with warnings about market-wide risksincluding high valuations, rising yields, and geopolitical uncertaintyand debate over whether index funds offer enough protection from a downturn.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

FDA acceptance of Intellias lonvo-z BLA for hereditary angioedema under priority review, following positive Phase 3 results, is the main catalyst, with a March 2027 decision date in focus. Traders are weighing the therapys potential as a one-time treatment against commercialization and financing risks, while debating the stocks muted, volatile reaction and perceived short-selling pressure.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobes quarterly results beat expectations, but the stocks weak reaction has kept attention on a softer forward outlook, slowing recurring-revenue growth, and whether AI adoption can translate into durable sales amid fears of AI disruption. Some traders see the cash generation and continued growth as evidence the selloff is excessive, while others remain concerned about monetization and the incoming CEO transition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FcRn Catalysts: $IMVT vs $ARGX $JNJ $UCBJY 
 
Immunovant, argenx, Johnson &amp; Johnson and UCB compete across an FcRn landscape where the indication and trial population matter. The comparison examines gMG, Graves disease, clinical setbacks, approved benchmarks and upcoming evidence. UCBJY trades OTC in the US. 
 
Full comparative research: https://www.merlintrader.com/imvt-argx-jnj-ucbjy-fcrn-catalyst-comparison/

Immunovant and three FcRn competitors: gMG, Graves disease, the CLE setback, upcoming milestones and the correct UCB OTC ticker.

Merlintrader Trading Pub

FcRn Catalysts: $IMVT Vs $ARGX $JNJ $UCBJY

StockTwits Web

Immunovant Inc

Argenx

Johnson & Johnson

 $UCBJY 
 
Immunovant, argenx, Johnson & Johnson and UCB compete across an FcRn landscape where the indication and trial population matter. The comparison examines gMG, Graves disease, clinical setbacks, approved benchmarks and upcoming evidence. UCBJY trades OTC in the US. 
 
Full comparative research: 